Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”).
“Our mission is to address significant unmet medical needs by developing cutting-edge therapies,” said Oragenics president Michael Redmond in the report. “There are over 3 million annual concussion occurrences in the U.S. and an estimated 69 million globally; however, it is believed that a substantial number, up to 50%, of cases go unreported. Given that there is still no FDA approval, and patients in need continue to face limited treatment options, the urgency to advance our efforts is greater than ever.”
To view the full press release, visit https://ibn.fm/WVxlB
About Oragenics
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (“mTBI”), also known as concussion, and for treating Niemann Pick Disease Type C (“NPC”), as well as proprietary powder formulation and an intranasal delivery device. For more information, visit the company’s website at www.Oragenics.com
NOTE TO INVESTORS: The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
